<DOC>
	<DOCNO>NCT02686086</DOCNO>
	<brief_summary>Treatment chronic obstructive pulmonary disease ( COPD ) incorporate various mode inhalation therapy . The response treatment dose dependent thus apply efficient device administer treatment integral . Evaluation efficacy nebulisation device treatment COPD limit . Technological development recent year lead new device optimize lung deposition reduce time need treatment . The aim study compare vibrate mesh jet nebuliser method deliver bronchodilator medication patient hospitalise acute exacerbation COPD , respect lung function efficacy spontaneously breathe patient .</brief_summary>
	<brief_title>A Pilot Comparison Study Vibrating Mesh Versus Standard Jet Nebuliser Bronchodilator Delivery COPD</brief_title>
	<detailed_description>Treatment chronic obstructive pulmonary disease ( COPD ) incorporate various mode inhalation therapy . The response treatment dose dependent thus apply efficient device administer treatment integral . Evaluation efficacy nebulisation device treatment COPD limit . Technological development recent year lead new device optimize lung deposition reduce time need treatment . The aim study compare vibrate mesh jet nebuliser method deliver bronchodilator medication patient hospitalise acute exacerbation COPD , respect lung function efficacy spontaneously breathe patient . Patients admit hospital exacerbation COPD prescribe regular nebulised bronchodilator ( combine salbutamol 2.5mg ipratropium 0.5mg ) recruit study . On one occasion day 3-7 admission perform pulmonary function test namely measurement Forced Expiratory Volume 1 second ( FEV1 ) , Forced Vital Capacity ( FVC ) , Inspiratory Capacity ( IC ) cough peak flow . They also complete Borg breathlessness score . Measurements record baseline ( pre-bronchodilator administration ) one hour post-nebulised bronchodilator . Patients randomise receive nebulised bronchodilator via standard hospital jet nebuliser via vibrate mesh nebuliser ( Aerogen Solo ) . Change lung function symptom measure baseline one-hour post nebulisation analyse look significant difference two group</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Hospital Inpatients admit acute exacerbation COPD Age &gt; 40 COPD Stage 24 moderate severe ( FEV1/FVC &lt; 0.70 ; FEV1 &lt; 80 % ) History physiciandiagnosed COPD COPD exacerbation day 2 day 7 admission Confusion Significant hypoxia/unstable medical condition Allergy contraindication salbutamol and/or ipratropium Pneumonia Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>